



PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	09/854,248		
		Filing Date	May 11, 2001		
		First Named Inventor	Salgaller, Michael L.		
		Art Unit	1644		
		Examiner Name	Gerald R. Ewoldt		
Sheet	1	of	2	Attorney Docket Number	020093-000810US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number ⁴	Kind Code ⁵ (if known)				
JS	AA	PCT	WO 94/20127		09/15/1994	Cytel Corporation		<input type="checkbox"/>
	AB	PCT	WO 97/04802		02/13/1997	Pacific Northwest Cancer Foundation		<input type="checkbox"/>
	AC	PCT	WO 00/06723		02/10/2000	Yeda Research and Development Company Ltd. at the Weizmann Institute of Science		<input type="checkbox"/>
	AD	PCT	WO 01/00225		01/04/2001	Epimmune Inc.		<input type="checkbox"/>

Examiner Signature	JS 3/27/02	Date Considered	
-----------------------	------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60592310 v1



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	09/854,248
				Filing Date	May 11, 2001
				First Named Inventor	Salgaller, Michael L.
				Art Unit	1644
				Examiner Name	Gerald R. Ewoldt
Sheet	2	of	2	Attorney Docket Number	020093-000810US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AE		HARRIS, D. <i>et al.</i> , "Immunological approaches to the treatment of prostate cancer," <i>Semin. Oncol.</i> , 26:439-447 (August 1999).	
AF		KAUFMANN, S. and HESS, J., "Impact of intracellular location of and antigen display by intracellular bacteria: Implications for vaccine development," <i>Immunol. Lett.</i> , 65:81-84 (January 1999).	
AG		KLAGGE, I. <i>et al.</i> , "Granulocyte-macrophage colony-stimulating factor elevates invariant chain expression in immature myelomonocytic cell lines," <i>Immunology</i> , 91:114-120 (1997).	
AH		STOVER, C.K. <i>et al.</i> , "New use of BCG for recombinant vaccines," <i>Nature</i> , 351:456-460 (June 6, 1991).	
AI		ZEOLI, C. <i>et al.</i> , "Expression of prostate specific molecules in BCG: A potential immunotherapeutic vaccine," Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000, <i>Proc. Am. Assoc. Cancer Res.</i> , 41:875 (April 1, 2001).	

Examiner Signature		Date Considered	
-----------------------	---	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.